Insulet Corporation introduced new Omnipod GO™, an insulin delivery device for people 18 years of age or older with type 2 diabetes who typically take daily long-acting insulin injections.
The key features of Omnipod GO include a tubeless and waterproof* Pod, which is the component that delivers the insulin. The Pod is available in seven different pre-programmed daily rates, ranging from 10 to 40 units per day.
It is specifically designed for people with type 2 diabetes who typically require daily injections of long-acting insulin. This self-contained portable system provides a fixed amount of continuous rapid-acting insulin for 72 hours.
Unlike other insulin delivery systems, Omnipod GO does not require a handheld device to control the Pod, making it more convenient for users.
The product has received clearance for use with U-100 insulins such as NovoLog®, Fiasp®, Humalog®, Admelog®, and Lyumjev®. It is intended to be used by people with type 2 diabetes, specifically those earlier in their treatment journey who can benefit from starting on Pod therapy instead of daily injections. If a patient's insulin needs increase, and they require both basal and bolus insulin, they can seamlessly transition to another Omnipod product.
The Omnipod GO aims to serve the more than three million individuals who rely on basal insulin or are transitioning to insulin therapy for the treatment of their type 2 diabetes. By simplifying the lives of people with diabetes, this new solution offers a convenient and effective method of insulin delivery.
